Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL3862996 | 0.94 | LMNA (0.57) | LMNAL3MBTL1SIGMAR1PTGS2ALDH1A1 | |
| Biphenyl SCHEMBL8087383 | 0.91 | LMNA (0.55) | LMNAL3MBTL1SIGMAR1PTGS2ALDH1A1 | |
| Tannin Pyrogallol SCHEMBL22288201 | 0.91 | LMNA (0.55) | LMNAL3MBTL1PTGS2ALDH1A1NPC1 | |
| Biphenyl SCHEMBL10925385 | 0.88 | LMNA (0.50) | LMNAL3MBTL1SIGMAR1PTGS2ALDH1A1 | |
| Biphenyl SCHEMBL8754510 | 0.82 | LMNA (0.44) | LMNAL3MBTL1PTGS2NPC1RAB9A | |
| Dimethylamine SCHEMBL15610806 | 0.79 | LMNA (0.80) | LMNA | |
| SCHEMBL4061902 | 0.79 | CYP1A2 (0.51) | LMNAALDH1A1NPC1RAB9ACYP1A2 | |
| SCHEMBL3476635 | 0.78 | LMNA (0.55) | LMNAL3MBTL1PTGS2CYP1A2CYP2D6 | |
| Benzenethiol SCHEMBL4312885 | 0.77 | LMNA (0.52) | LMNAL3MBTL1SIGMAR1NPC1TAAR1 | |
| Chlorobenzene SCHEMBL108740 | 0.77 | LMNA (0.52) | LMNAL3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838538-B1 | CYCLOPROPANECARBOXYLATE ESTERS OF PURINE ANALOGUES | ANNJI PHARM CO LTD (CN) | 2017-03-15 | — | — | EP | disclosed |
| CN-104394868-A | Cyclopropane carboxylic acid esters of purine analogs | ANNJI PHARM CO LTD | 2015-03-04 | — | — | CN | disclosed |
| US-8969361-B2 | Cyclopropanecarboxylate esters of purine analogues | Annji Pharmaceutical Co., Ltd. (TW) | 2015-03-03 | — | — | US | disclosed |
| US-20130281517-A1 | CYCLOPROPANECARBOXYLATE ESTERS OF PURINE ANALOGUES | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281517-A1 | CYCLOPROPANECARBOXYLATE ESTERS OF PURINE ANALOGUES | TYMP, PNP, PAICS | LMNA 3187/4885L3MBTL1 1879/4885SIGMAR1 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.